Met Non Small Cell Cancer Registry (MOMENT)
- Conditions
- Cancer
- Registration Number
- NCT05376891
- Brief Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.
- Detailed Description
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 700
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
- Participants who are enrolled in a clinical trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best Overall Response (BOR) Through study completion, up to approximately 4.9 years Overall Survival (OS) Through study completion, up to approximately 4.9 years Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Up to approximately 4.9 years Number of Participants with Adverse Events (AEs) Up to approximately 4.9 years Number of Participants with Adverse Reactions (ARs) Up to approximately 4.9 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (64)
The Ohio State University Wexner Medical Center
🇺🇸Columbus, Ohio, United States
Holy Cross Health
🇺🇸Fort Lauderdale, Florida, United States
AZ Nikolaas
🇧🇪Sint-Niklaas, Belgium
Ottawa Hospital General Campus
🇨🇦Ottawa, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Canada
Centre Hospitalier de Cholet
🇫🇷Cholet, France
FN Olomouc
🇨🇿Olomouc, Czechia
University Hospital Na Bulovce
🇨🇿Praha 8, Czechia
CHRU Lille
🇫🇷Lille cedex, France
Hôpital du Scorff
🇫🇷Lorient, France
Institut Curie - Centre de Lutte Contre le Cancer (CLCC)
🇫🇷Paris Cedex 05, France
Centre Leon Berard
🇫🇷Lyon Cedex 08, France
Klinikum Chemnitz GmbH
🇩🇪Chemnitz, Germany
CHU de Toulouse Hopital Larrey
🇫🇷Toulouse, France
Hospital Tenon & University Paris 6
🇫🇷Paris, France
Thoraxklinik-Heidelberg gGmbH
🇩🇪Heidelberg, Germany
KKH Grosshansdorf GmbH
🇩🇪Grosshansdorf, Germany
Klinik Löwenstein GmbH
🇩🇪Löwenstein, Germany
Assuta Ashdod Medical Center
🇮🇱Ashdod, Israel
Rabin Medical Center Oncology Beilinson Campus
🇮🇱Petach Tikva, Israel
VU Medisch Centrum
🇳🇱Amsterdam, Netherlands
Universitair Medisch Centrum Groningen - Department of Medical Oncology
🇳🇱Groningen, Netherlands
Clinica Tres Torres
🇪🇸Barcelona, Spain
Centro Integral Oncologico Clara Campa
🇪🇸Madrid, Spain
Hospital Regional Universitario de Malaga - Hospital General
🇪🇸Malaga, Spain
Complejo Hospitalario Universitario Insular-Materno Infantil
🇪🇸las Palmas de Gran Canaria, Spain
Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. Rosell
🇪🇸Barcelona, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospidal Universitario Ntra. Sra. De Valme
🇪🇸Sevilla, Spain
Universitetssjukhuset i Linköping
🇸🇪Linköping, Sweden
Hospital Universitari i Politecnic La Fe de Valencia
🇪🇸Valencia, Spain
Bedford General Hospital
🇬🇧Bedford, United Kingdom
Birmingham Heartlands Hospital
🇬🇧Birmingham, United Kingdom
Royal Bournemouth Hospital
🇬🇧Bournemouth, United Kingdom
Royal Surrey County Hospital
🇬🇧Guildford, United Kingdom
The Royal Marsden Hospital
🇬🇧Chelsea, United Kingdom
Northwick Park Hospital
🇬🇧Harrow, United Kingdom
Clatterbridge Cancer Centre - Liverpool
🇬🇧Liverpool, United Kingdom
Preston Hospital
🇬🇧Preston, United Kingdom
Klinik Floridsdorf
🇦🇹Wien, Austria
Turun Yliopistollinen Keskussairaala
🇫🇮Turku, Finland
Bnei-Zion Medical Center
🇮🇱Haifa, Israel
Carmel Medical Center
🇮🇱Haifa, Israel
Rambam Medical Center - PPDS
🇮🇱Haifa, Israel
Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
🇵🇹Lisboa, Portugal
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Klinikum Klagenfurt Am Woerthersee
🇦🇹Klagenfurt am Wörthersee, Austria
Centro Hospitalar do Porto E.P.E. Hospital de Santo António
🇵🇹Porto, Portugal
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
🇵🇹Porto Covo, Portugal
AZ Delta
🇧🇪Roeselare, Belgium
University Hospital of Tampere
🇫🇮Tampere, Finland
Haemek Medical Center
🇮🇱Afula, Israel
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Leiden University Medical Center
🇳🇱Leiden, Netherlands
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Istituto Nazionale Dei Tumori
🇮🇹Milano, Italy
AOU dell'Università degli Studi della Campania Luigi Vanvitelli
🇮🇹Napoli, Italy
I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS
🇮🇹Rome, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
🇮🇹Torino, Italy
Ospedale di Circolo
🇮🇹Varese, Italy
Centro Oncologico MD Anderson
🇪🇸Madrid, Spain
Charing Cross Hospital
🇬🇧London, United Kingdom